Date |
Company |
Compound |
Disease |
Type of agreement |
Therapeutic area |
Type of Information |
2017-07-24 |
Seattle Genetics (USA - WA) Genentech, a member of Roche Group (USA - CA - Switzerland) |
SGN-LIV1A and atezolizumab |
triple-negative breast cancer (TNBC) |
clinical research |
Cancer - Oncology |
Clinical research agreement |
2017-07-24 |
4D Molecular Therapeutics (USA - CA) the Foundation Fighting Blindness (USA - MD) |
intravitreal gene therapeutics using 4DMT-proprietary AAV vectors. |
inherited retinal diseases |
collaboration |
Rare diseases - Genetic diseases - Ophtalmological diseases |
Collaboration agreement |
2017-07-21 |
Alligator Bioscience (Sweden) Aptevo Therapeutics (USA - WA) |
ALG.APV-527 |
|
development |
Cancer - Oncology |
Development agreement |
2017-07-20 |
Roche (Switzerland) Oryzon Genomics (Spain) |
inhibitors of Lysine Specific Demethylase-1 (LSD1; KDM1A) including ORY-1001 (RG6016) |
acute myeloid leukaemia |
research - development - licensing |
Cancer - Oncology |
Termination of an agreement |
2017-07-20 |
Recipharm (Sweden) LIDDS (Sweden) |
Liproca®Depot |
prostate cancer |
production - manufacturing |
Cancer - Oncology |
Production agreement |
2017-07-20 |
Ablynx (Belgium) Sanofi (France) |
Nanobody®-based therapeutics |
immune mediated inflammatory diseases |
research - licensing |
Immunological diseases - Inflammatory diseases |
Licensing agreement |
2017-07-20 |
Emergent BioSolutions (USA - MD) GSK (UK) |
raxibacumab |
anthrax |
product acquisition |
Infectious diseases |
Product acquisition |
2017-07-20 |
Auris Medical (Switzerland) Otifex Therapeutics (Australia) |
AM-125 (betahistine dihydrochloride) |
Meniere's disease and other vestibular disorders |
product acquisition |
Otorhinolaryngology |
Product acquisition |
2017-07-19 |
GSK (UK) |
UK manufacturing network |
|
restructuring |
Infectious diseases - Respiratory diseases |
Restructuring |
2017-07-19 |
Sutro Biopharma (USA - CA) |
board of directors |
|
nomination |
Infectious diseases |
Nomination |
2017-07-19 |
Sagetis Biotech (Spain) |
member of the scientific advisory board
|
|
nomination |
Cancer - Oncology - Rare diseases |
Nomination |
2017-07-18 |
Novimmune (Switzerland) Baxalta (USA - IL) now Shire (UK - USA) |
novel bispecific antibodies based on kappa-lambda bispecific antibody technology |
hemophilia A |
R&D - research |
Rare diseases - Genetic diseases - Hematological diseases |
Research agreement |
2017-07-18 |
Daiichi Sankyo (Japan) Zymeworks (Canada) |
Azymetric™ and Effector Function Enhancement and Control Technology (EFECT™) platforms |
|
licensing - collaboration |
Cancer - Oncology |
Milestone |
2017-07-18 |
4SC (Germany) Maruho (Japan) |
inhibitor of the Kv1.3 ion channel |
|
licensing |
Autoimmune diseases - Dermatological diseases |
Licensing agreement |
2017-07-18 |
Autolus (UK) |
chief operating officer, chief business officer, vice-president |
|
nomination |
Cancer - Oncology |
Nomination |
2017-07-18 |
Audentes Therapeutics (USA - CA) |
Vice President Scientific Affairs, Europe |
|
nomination |
Rare diseases - Genetic diseases |
Nomination |
2017-07-17 |
Biogen (USA - MA) Isis Pharmaceuticals , now Ionis Pharmaceuticals (USA - CA) |
antisense therapies for neurological diseases |
neurological diseases, neuromuscular diseases |
development |
Neurological diseases - Neuromuscular diseases - Neurodegenerative diseases |
Milestone |
2017-07-14 |
Emergent BioSolutions (USA - MD) Sanofi (France) |
ACAM2000® (Smallpox (Vaccinia) Vaccine, Live) business
|
smallpox |
product acquisition |
Infectious diseases |
Product acquisition |
2017-07-13 |
Achaogen (USA - CA) |
|
|
nomination |
Infectious diseases |
Nomination |
2017-07-13 |
Radius Health (USA - MA) Teijin (Japan) |
Eladynos®/Tymlos® (abaloparatide) |
osteoporosis |
development - licensing |
Bone diseases |
Licensing agreement |